These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 22023894)

  • 41. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of menopause: executive summary of recommendations.
    Goodman NF; Cobin RH; Ginzburg SB; Katz IA; Woode DE;
    Endocr Pract; 2011; 17(6):949-54. PubMed ID: 22193145
    [No Abstract]   [Full Text] [Related]  

  • 42. Comments about the severe fracture concept used in the 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis, by Briot et al.
    Pouilles JM
    Joint Bone Spine; 2012 Oct; 79(5):527-8; author reply 528-9. PubMed ID: 23041470
    [No Abstract]   [Full Text] [Related]  

  • 43. How do women develop fragile bones?
    Reeve J
    J Steroid Biochem Mol Biol; 2000 Nov; 74(5):375-81. PubMed ID: 11162947
    [No Abstract]   [Full Text] [Related]  

  • 44. Not all SERMs are created equal: chapter 2.
    Goldstein SR
    Menopause; 2015 Aug; 22(8):802-3. PubMed ID: 26102533
    [No Abstract]   [Full Text] [Related]  

  • 45. Estrogen and postmenopausal osteoporosis.
    Gordan GS
    Ann Intern Med; 1993 Jan; 118(2):155; author reply 156. PubMed ID: 8416313
    [No Abstract]   [Full Text] [Related]  

  • 46. [Calcitonin: with caution].
    Perspect Infirm; 2013; 10(5):63. PubMed ID: 24358680
    [No Abstract]   [Full Text] [Related]  

  • 47. Morphea-like skin lesions reported in the phase 3 Long-Term Odanacatib Fracture Trial (LOFT) in postmenopausal women with osteoporosis.
    Saag KG; de Villiers TJ; Alexandersen P; Jacobe H; Kovarik C; Werth VP; Leung A; Desai-Merchant A; Mattaliano J; Gurner D
    J Am Acad Dermatol; 2021 Apr; 84(4):1113-1119. PubMed ID: 32553680
    [No Abstract]   [Full Text] [Related]  

  • 48. Bimonthly update. Therapy and clinical trials.
    Bachorik PS
    Curr Opin Lipidol; 2001 Feb; 12(1):89-91. PubMed ID: 11176209
    [No Abstract]   [Full Text] [Related]  

  • 49. Osteoporosis after 60.
    Smith R
    BMJ; 1990 Nov; 301(6759):1047. PubMed ID: 2249061
    [No Abstract]   [Full Text] [Related]  

  • 50. Thyroid hormone, osteoporosis, and estrogen.
    Cooper DS
    JAMA; 1994 Apr; 271(16):1283-4. PubMed ID: 8151904
    [No Abstract]   [Full Text] [Related]  

  • 51. Predictors of difficulty when discontinuing postmenopausal hormone therapy.
    Grady D; Ettinger B; Tosteson AN; Pressman A; Macer JL
    Obstet Gynecol; 2003 Dec; 102(6):1233-9. PubMed ID: 14662209
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Effect of tamoxifen on the bone mass].
    Lima FA; Szejnfeld VL; Baracat EC; Atra E; Lima GR
    Rev Assoc Med Bras (1992); 1992; 38(4):231-3. PubMed ID: 1340384
    [No Abstract]   [Full Text] [Related]  

  • 53. Concerns on modeling postmenopausal osteoporosis on young female rats.
    Lelovas P; Dontas I
    J Orthop Surg Res; 2019 Dec; 14(1):450. PubMed ID: 31852495
    [No Abstract]   [Full Text] [Related]  

  • 54. Response to Letter to the Editor: Concerns on modeling postmenopausal osteoporosis in young female rats.
    Rocabado JMR; Kaku M; Nozaki K; Ida T; Kitami M; Aoyagi Y; Uoshima K
    J Orthop Surg Res; 2019 Dec; 14(1):451. PubMed ID: 31852490
    [No Abstract]   [Full Text] [Related]  

  • 55. Effect on bone of withdrawal of oestrogen therapy.
    Aitken JM
    Lancet; 1979 Jul; 2(8135):195-6. PubMed ID: 89300
    [No Abstract]   [Full Text] [Related]  

  • 56. Oral surgery: The drug holiday.
    Shiels D; Goodall A
    Br Dent J; 2017 Oct; 223(7):464. PubMed ID: 29026231
    [No Abstract]   [Full Text] [Related]  

  • 57. Bones of contention.
    Pini P
    Lancet; 1993 Apr; 341(8850):950-1. PubMed ID: 8096280
    [No Abstract]   [Full Text] [Related]  

  • 58. Editorial overview: Musculoskeletal: Where are we with treating musculoskeletal disorders?
    Orriss IR; MacRae VE
    Curr Opin Pharmacol; 2016 Jun; 28():iv-vi. PubMed ID: 27067741
    [No Abstract]   [Full Text] [Related]  

  • 59. Characterisation of Bone Beneficial Components from Australian Wallaby Bone.
    Lao W; Jin X; Tan Y; Xiao L; Padula MP; Bishop DP; Reedy B; Ong M; Kamal MA; Qu X
    Medicines (Basel); 2016 Aug; 3(3):. PubMed ID: 28930133
    [No Abstract]   [Full Text] [Related]  

  • 60. Duration of treatment in postmenopausal osteoporosis: how long to treat and what are the consequences of cessation of treatment?
    Laster AJ; Tanner SB
    Rheum Dis Clin North Am; 2011 Aug; 37(3):323-36, v. PubMed ID: 22023894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.